Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Biofluid Biopsies
Conferences  \  Biofluid Biopsies and Companion Diagnostics 2014  \  Biofluid Biopsies  \  Agenda  \  Farideh Bischoff
RegisterLogin

Farideh Bischoff's Biography


Farideh Bischoff, Executive Director, Silicon Biosystems Inc

Dr. Bischoff received her Ph.D. in Cancer Biology from University of Texas Graduated School for Biomedical Sciences (Houston, TX) followed by postdoctoral training at M.D. Anderson Cancer Center. She completed the human molecular genetics and cytogenetic fellowship program prior to joining as fulltime faculty member in the Department of Obstetrics and Gynecology at Baylor College of Medicine. She is an expert in clinical and molecular human cytogenetics and is well known in the fields of rare fetal and tumor cell recovery for non-invasive molecular diagnosis. She has expertise in clinical study designs and commercial assay development within the fields of prenatal, oncology, infertility and pre-implantation genetic diagnosis.

Farideh Bischoff Image

Recovery of Pure Tumor Cell Populations using the DEPArray System: Enabling Molecular Profiling and NGS applications to CTCs and FFPE

Monday, 27 October 2014 at 14:30

Add to Calendar ▼2014-10-27 14:30:002014-10-27 15:30:00Europe/LondonRecovery of Pure Tumor Cell Populations using the DEPArray System: Enabling Molecular Profiling and NGS applications to CTCs and FFPESELECTBIOenquiries@selectbiosciences.com

Silicon Biosystems has combined the ability to manipulate individual cells using DEP (dielectrophoresis) technology with high quality image-based cell selection to create the DEPArray™ System. This automated platform enables identification and recovery of specific individual cells of interest from complex, heterogeneous samples; enabling analysis of pure cell populations.  Given that molecular testing of CTCs and FFPE tissue can often be compromised due to specimen size, heterogeneity, and/or the percentage of normal cells present, we have developed methods that enable reliable recovery of pure tumor cell populations that are amenable to downstream molecular profiling and NGS.  We will present results from case studies to support these claims.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors